A study found that PD-L1, PD-L2 and tumor mutation burden from a comprehensive genomic and transcriptomic profiling test independently predicted Keytruda (pembrolizumab) benefit in pan-solid tumors—and when combined in a multivariate signature score—predicted benefit better than PD-L1 or TMB alone.
With a growing backlog at NIH and Columbia University’s grants getting canceled over alleged antisemitism, where does that leave NCI-designated cancer centers?
